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Abstract 
For the broad identification of a risk for a serious mental disorder, valid and reliable screeners are 
needed to detect those most likely benefitting from a time-consuming and costly in-depth clinical 
assessment. In the early detection of psychoses, multiple screeners for an ultra-high risk have already 
been suggested. Yet, no screener explicitly targets an increased risk according to the basic symptom 
(BS) criteria. We therefore explored the Frankfurt Complaint Questionnaire (FCQ) as a potential 
screener for BS in comparison to their gold-standard clinical assessment using the Schizophrenia 
Proneness Instrument (SPI-A/SPI-CY) by examining its convergent (agreement between screener and 
gold-standard, calculated by the overall percentages of agreement between FCQ and SPI-A/SPI-CY) 
and concurrent (degree to which a screener can identify individuals with the target condition, 
examined by diagnostic accuracy measures calculated using thresholds of receiver operating 
characteristic curves) validity. The sample consisted of 81 patients of a psychosis early detection 
service (41 with an at-risk mental state or psychosis, and 40 with a nonpsychotic mental disorder). 
Only two visual perception disturbances reached a beyond chance level of agreement between FCQ 
and SPI-A/SPI-CY. For the BS-criteria ‘cognitive perceptive basic symptoms’ and ‘cognitive 
disturbances’, only insufficient agreement between assessment techniques were detected with Cohen’s 
kappa being 0.228 and 0.130, respectively, with an overestimation by the FCQ. Diagnostic likelihood 
ratios indicated only a clinically irrelevant increase in the probability of detecting BS criteria, thus, the 
concurrent validity of both the total of all and of only criteria-relevant FCQ-items was insufficient. 
Both concurrent and convergent validity of the FCQ were poor, and the FCQ dramatically 
overestimated clinician-assessed risk. Our results suggest that the FCQ should not be used as a 
screener for BS-criteria and that the convergent validity is not guaranteed on the basis of face validity 
alone, but has to be formally assessed. 
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1. Introduction 
An indicated prevention of first-episode psychosis has become increasingly important in mental health 
research for its potential to alter the course of psychotic disorders whose nature, i.e. neurobiological 
and psychosocial underpinnings, is still largely unknown (Fusar-Poli et al. 2013; Schmidt et al. 2015; 
Schultze-Lutter et al. 2015). This prevention approach selectively targets patients who already seek 
help for mental problems including early subclinical signs and symptoms which represent primarily 
risk indicators or early expressions of the disorder (Mrazek and Haggerty 1994). As the majority of 
first-episode psychotic disorders, and in particular schizophrenic disorders, are preceded by a 
prodromal phase of several years in that help might be already sought (Schultze-Lutter et al. 2010; 
Schaffner et al. 2012), they offer a good starting for an indicated prevention. Thus in the past two 
decades, efforts have been put into identifying potential sensitive and specific clinical high risk criteria 
of psychosis to be assessed in clinical interviews by trained mental health professionals (Schmidt et al. 
2015; Schultze-Lutter et al. 2015; Fusar-Poli et al. 2015). In this framework, a “clinical high risk state” 
differs from a “prodromal state” that inevitably leads to the full-blown disorder in that it can remit – 
temporarily or persistently – or even become chronic (Lin et al. 2015). While different approaches 
have been studied, two major sets of clinical high risk criteria, are currently used to identify an 
increased psychosis-risk (Fusar-Poli et al. 2013, 2015; Schultze-Lutter et al. 2015): The ultra-high risk 
criteria that mainly rely on attenuated or transient psychotic symptoms, and the basic symptom (BS) 
criteria that rely on subjective disturbances in thought and perception processes (Table 1). Clinical 
high risk criteria are fulfilled if the defined requirements of onset and frequency are met, with no 
further differentiation of severity of risk. Of these, the European Psychiatric Association recommends 
to alternatively use one of the following three clinical high risk criteria for an early detection of 
psychoses: (1) at least any one attenuated or (2) at least any one transient psychotic symptom and (3) 
at least any two self-experienced and self-reported cognitive BS with a score of at least ‘3’ (= weekly 
occurrence within the past 3 months) in the Schizophrenia Proneness Instrument (Schultze-Lutter et 
al., 2015). It is further recommended that their assessment in clinical interviews should only be carried 
out by trained specialists with sufficient experience in clinical high risk (Schultze-Lutter et al., 2015). 
Yet, the application of these semi-structured clinical interviews is time-consuming, requires training, 
and is typically carried out in specialised centres to that patients are mainly referred (Fusar-Poli et al. 
2013; Schultze-Lutter et al. 2013; Tandon et al. 2012).  
Given the waste of resources associated with inadequate referral, the ability to conduct economic, 
valid and reliable pre-diagnostic screening of individuals with potentially increased psychosis-risk 
would be of great value. Several, mainly self-report instruments have been proposed to this end (Kline 
and Schiffman 2014) that are either adaptions of questionnaires originally developed to assess 
psychotic-like experiences within the community, such as the Community Assessment of Psychotic 
Experiences (Yung et al. 2009), or developed specifically for ultra-high risk criteria, such as the 
Prodromal Questionnaire (Ising et al. 2012) or PRIME Screen (Miller et al. 2004). Only two screeners 
include the assessment of some BS, the PROD-Screen (Heinimaa et al. 2003) and the Eppendorf 
Schizophrenia Inventory (Maß et al. 2000). Yet both instruments were not constructed with regard to 
BS criteria, and while the Eppendorf Schizophrenia Instrument only includes questions on four of the 
14 criteria-relevant BS – mainly taken from the Frankfurt Complaint Questionnaire (FCQ; Süllwold 
1991; Süllwold and Huber 1986), the PROD-Screen includes 6 statements, yet all of them are 
compound statements tapping into several criteria-relevant as well as criteria-irrelevant BS at once or 
even into BS and (attenuated) psychotic symptoms at once. Thus, unsurprisingly, both have not been 
studied for their ability to specifically detect BS criteria (Heinimaa et al. 2003; Maß et al. 2000). 
-Table 1- 
Furthermore, none of these screeners has yet been examined for its convergent validity, i.e., the degree 
to which an instrument actually measures the same phenomena as the gold standard instrument (Dawe 
et al. 2002; Stinson et al. 2006). The gold standard in detection of psychosis-risk is the assessment of 
clinical high risk criteria within a semi-structured clinical interview by mental health professionals 
trained in the respective instrument; in case of BS criteria, this is either the adult or the child and youth 
version of the Schizophrenia Proneness Instrument (Schultze-Lutter et al. 2015). Importantly, 
convergent validity is not guaranteed on the basis of face validity alone, but has to be formally 
assessed (Jaeschke et al. 1994). 
BS are self-experienced subclinical disturbances in mentation including cognition and perception 
(Gross 1989; Huber 1966; Huber and Gross 1989). As BS are by definition subjective and 
predominately remain private and apparent only to the affected person, their assessment in clinical 
interviews completely relies on patients’ reports regarding the novelty and abnormality of their 
experiences. BS criteria may therefore be an even better and more suitable target for a self-report 
screener than the symptomatic ultra-high risk phenomena whose abnormal nature might not be 
perceived by the patient or might be hard to locate on the proposed psychosis continuum, i.e., might be 
hard to distinguish from normal experiences (Johns and van Os 2001; Fusar-Poli et al. 2014). 
BS were first operationalised by a semi-structured clinical interview in the 142-item Bonn Scale for 
the Assessment of Basic Symptoms (Gross et al. 1987) with shorter measures, the Schizophrenia 
Proneness Instrument, Adult (SPI-A; Schultze-Lutter et al. 2007), and Child and Youth version (SPI-
CY; Fux et al. 2013; Schultze-Lutter et al. 2012a), subsequently evolving from it (Schultze-Lutter et 
al. 2012b) and now being used as the gold standard of their assessment (Schultze-Lutter et al. 2015). 
In close collaboration with Gerd Huber’s work group developing the Bonn Scale for the Assessment 
of Basic Symptoms, the Frankfurt Complaint Questionnaire (FCQ; Süllwold 1991; Süllwold and 
Huber 1986) was developed by the work group of Lilo Süllwold as a self-report measure of the same 
subjective phenomena with its item formulations based on face validity. With 10 of the 14 criteria-
relevant BS, the FCQ still offers – in theory – the most comprehensive self-rating assessment of BS 
criteria, although it has been repeatedly criticized for its lack of diagnostic validity for schizophrenia 
(e.g., Maß 2005). Furthermore, if the FCQ would indeed measure the same phenomena as the Bonn 
Scale for the Assessment of Basic Symptoms or its successors SPI-A/SPI-CY, its items should possess 
excellent convergent validity with the corresponding interview items, and, consequently, the FCQ 
should have at least satisfactory concurrent validity for a clinical high risk state according to BS 
criteria. The FCQ has already demonstrated good reliability and internal consistency (Loas et al. 2011; 
Yon et al. 2008), and therefore may well serve as a useful screener for BS criteria. 
This study investigated (i) the convergent validity of BS using the FCQ compared to their clinical 
assessment using SPI-A/SPI-CY (the gold standard), and (ii) its concurrent validity i.e., the degree to 
which the FCQ can identify the individuals who currently have a clinician-determined psychosis-risk 
according to BS criteria. 
 
2. Material and Methods 
2.1. Sample 
The sample comprised 81 patients aged 8-40 years of the Bern Early Recognition and Intervention 
Centre for Mental Crises (FETZ-Bern) (Table 2; demographics of the ≥16-year-olds are provided in 
Supplementary Table 1). Exclusion criteria were somatic and/or psychotropic drug-use related 
conditions that might account for mental problems, and insufficient reading skills in German. In total, 
41 patients (50.6%) were either diagnosed with a psychotic disorder or fulfilled BS and/or ultra-high 
risk criteria. The remaining 40 patients (49.4%) met criteria for a nonpsychotic mental disorder or 
complained about only subthreshold nonpsychotic mental problems according to the Mini-
International Neuropsychiatric Interview (Sheehan et al. 1998) (Table 2). 
-Table 3- 
2.2. Instruments 
SPI-A/SPI-CY were used for the assessment of clinician-rated BS (henceforth BS-SPI) and BS criteria 
(Table 1), namely cognitive-perceptive BS (COPER) and cognitive disturbances (COGDIS). With 
each item assessing exactly one BS, SPI-A/SPI-CY rank BS on a severity scale according to the 
maximum frequency of their occurrence within the past three months ranging from 0 (absent=BS has 
not occurred in the past 3 months) to 6 (extreme=BS has occurred daily over some time within the past 
three months). Symptoms may also be rated as 7 (BS has always been present in same severity; trait), 
8 (BS is definitely present, but its frequency of occurrence is unknown), and 9 (presence of BS can 
neither be unambiguously ruled in nor out). For the purpose of this study, BS-SPI were recoded 
according to their presence into binary items for better correspondence with the binary rated FCQ-
items: 1 (presence) was assigned to scores between 1-8 (i.e., all scores that clearly indicate the 
presence of the BS) and 0 (absence) was assigned to scores of 0 and 9 (i.e., scores clearly indicating 
the absence of the BS or only its ambiguous presence). 
Presence and absence of self-reported BS (henceforth BS-FCQ) were assessed using the FCQ that 
comprises of 98 partially overlapping items referring to identical phenomena (Tables 3 and 4). Each 
item is designed as a statement describing a certain complaint, and the patient is instructed to indicate 
whether he/she has experienced such a complaint lately – irrespective of its frequency – by ticking 
either the Yes or the No box. Complaints only experienced in the past but not lately have to be 
indicated by ticking the Yes box and adding “formerly” next to it. For the focus of the SPI-A/SPI-CY 
on the past three months, these FCQ-items were considered as absent in the analyses to avoid a bias 
towards over-report of BS in the FCQ compared to SPI-A/SPI-CY by different assessment periods. 
Assignment of BS-SPI and BS-FCQ items followed the originally described item correspondence 
between the FCQ and Bonn Scale for the Assessment of Basic Symptoms (Süllwold and Huber 1986). 
Yet, as this description included only a subgroup of items however, item correspondences were 
complemented by Frauke Schultze-Lutter. (Tables 3 and 4). 
 
2.3. Procedure 
In the FETZ-Bern, patients are assessed for BS by well-trained clinical psychologists. All raters were 
initially trained (concordance rate with expert rating after 10 training sessions 91%) and, to further 
ensure high data quality over time, are continuously supervised in SPI-A/SPI-CY and SIPS 
assessments by Frauke Schultze-Lutter, expert in both assessments and main author of SPI-A/SPI-CY. 
Patients also complete a battery of questionnaires including the FCQ. All patients (and their 
parents/guardians in the case of minors) provided written informed consent to the scientific use of 
their anonymous clinical data. The local ethical committee had approved the study. 
 
2.4. Statistical analysis 
Using SPSS 21.0, the convergent validity was calculated by the overall percentages of agreement 
(concordance rate; CR) between the presence of BS-SPI and BS-FCQ. Where several FCQ-items 
corresponded to one BS-SPI, both single FCQ-items and a compound rating (presence of any one 
item) were examined. To control for effects of chance, agreement on the presence of symptoms and 
criteria was additionally calculated using Cohen’s kappa (κ) statistic. A disadvantage generally 
associated with use of κ is its dependence on the prevalence of an event (Byrt et al. 1993):  tends to 
decrease when a response/event is rare, even if the CR is high. In the absence of a satisfactory 
mathematical solution to this problem, we followed the approach for the appraisal of  suggested by 
Burn and Weir (2011) and, additionally, calculated the prevalence index. The prevalence index reports 
values between -1 and 1, and is 0 when both responses are equally probable (i.e., their prevalence is 
50%). According to Burn et al. (2009), κ≥0.40 and CR≥75% are considered clinically useful. When 
information is contradictory, such as when CR exceeds its threshold but κ falls below it, the 
prevalence index should be considered. With the prevalence index approaching an absolute value of 1, 
the likelihood of an underestimation of  increases, and more attention should be paid to CR. 
Furthermore, concurrent validity (often reported as “discriminant” validity) and diagnostic accuracy of 
the FCQ for BS criteria were examined. The FCQ provides no information on symptom onset or 
frequency and so BS criteria had to be redefined to avoid a systematic bias resulting from the unequal 
consideration of onset and frequency in the assessment modes. To this, psychosis-risk according to 
SPI was re-defined as at least 1 of the binary BS included in COPER and/or at least 2 of those 
included in COGDIS. This re-calculation resulted in n=49 patients with COPER and n=19 with 
COGDIS. 
To examine the concurrent validity of the FCQ-total and the FCQ criteria-relevant BS total (BS-
criteria-FCQ), receiver operating characteristic curves were first calculated to detect the optimal 
threshold for discriminating ‘BS-risk’ from ‘no BS-risk’ patients. Using these thresholds, diagnostic 
accuracy measures (sensitivity, specificity, positive and negative predictive values, positive and 
negative likelihood ratios (LR)) were then calculated. LRs guided the estimation of concurrent validity 
for the availability of interpretation guidelines (Jaeschke et al. 1994) that are missing for other 
accuracy measures that can only be interpreted by less reliable rules-of-thumb (Boyko 1994; Jaeschke 
et al. 1994). 
An age effect was examined by sensitivity analyses in that all analyses were additionally performed on 
a subsample ≥16-year-olds (n=62) and compared for a systematic bias with the overall results. 
 
3. Results 
3.1. Criteria-relevant basic symptoms 
Of the 34 BS-FCQ that correspond to criteria-relevant BS-SPI, only two visual perception 
disturbances (FCQ 24, 29; Table 3) were unequivocally reliable in terms of showing both sufficient 
CR of  ≥75% and beyond-chance-agreement of κ>0.40. Furthermore, two other visual perception 
disturbances (FCQ 51, 84) might be reliably assessable with the FCQ, as they both possessed a 
sufficient CR and a low κ possibly caused by a high prevalence index. Altogether 15 BS-FCQ had to 
be regarded as an unreliable assessment despite demonstrating sufficient CRs; in these items, an 
insufficient κ was unlikely due to a high prevalence index. All remaining 15 BS-FCQ relevant for BS 
criteria showed no indication of being an adequate estimate of clinician-assessed BS-SPI as both their 
CRs and κ were below the threshold for clinical usefulness (Table 3). 
 
3.2. Basic symptom criteria 
Both BS criteria, COPER and COGDIS, were overestimated by the FCQ by about 30% and 60%. Both 
CRs and κ fell clearly below the threshold for clinical usefulness therefore (Table 3). 
-Table 3- 
 
3.3. Criteria-irrelevant basic symptoms 
Of the 37 BS-FCQ not included in the BS criteria, none was unequivocally reliable in terms of 
showing both a sufficient CR and κ. One body perception disturbance, FCQ 18, might however 
reliably assess its corresponding BS-SPI (D.8), as it possessed good CR and low κ possibly caused by 
a high prevalence index (Table 4). The other body perception disturbance included in FCQ and SPI, 
FCQ 9, had to be regarded as unreliable despite its sufficient CR as its low κ value was unlikely 
caused by a high PI. All remaining 35 criteria-irrelevant BS-FCQ showed no indication of being an 
adequate estimate of BS-SPI, as both their CRs and κ fell below the thresholds for clinical usefulness 
(Table 4). 
-Table 4- 
 
3.4. Concurrent validity 
Analyses of the area under the receiver operating characteristic curves of both the FCQ-total and BS 
criteria-FCQ revealed unsatisfactory areas under the curve of 0.737 (95% CI=0.623–0.851, p<0.001) 
and 0.758 (95% CI=0.651–0.865, p<0.001) with regards to identifying BS-risk patients. When 
emphasising non-exclusion of potential risk patients (i.e. high sensitivity), the best threshold for 
differentiating ‘BS-risk’ from ‘no BS-risk’ were a FCQ-total ≥5 (sensitivity=0.978, 
specificity=0.161) and BS criteria-FCQ ≥1 (sensitivity=0.978, specificity=0.194). When trying to 
optimise both sensitivity and specificity (as reported for most screeners for UHR status), the best 
threshold were FCQ-total ≥24 (sensitivity=0.733, specificity=0.645) and BS criteria-FCQ ≥8 
(sensitivity=0.644, specificity=0.677). The diagnostic accuracy measures of FCQ-total and BS criteria-
FCQ were unsatisfactory (Table 5, Figure 1). 
-Table 5 and Figure 1- 
 
3.5. Age effect  
Sensitivity analyses gave no indication of an age effect. In line with the overall results, convergent and 
concurrent validity were mainly insufficient (Supplementary Tables 2-4). 
 
4. Discussion 
The early detection of rare but severe conditions requires easy and broadly applicable screeners to 
guide the referral of appropriate patients to in-depth diagnostic assessment (Cadman et al. 1984). 
Psychosis is one such condition. In addition to reliability, an ideal screener would demonstrate 
excellent concurrent validity by (i) ruling in all patients with the target condition while (ii) ruling out a 
considerable proportion of those without it. In a practical sense then, a screener for psychosis-risk 
should therefore possess a sensitivity approaching 100%, a negative diagnostic LR0.1 that indicates a 
‘large and often conclusive’ change from pre-screen to post-screen probability of the absence of 
psychosis-risk (Jaeschke et al. 1994), and a positive predictive value that is greatest in settings in 
which the prevalence of the condition is highest, i.e., greater in clinical settings than in community 
settings (Cadman et al. 1984). At the same time, but secondary to the above, a screener should also 
possess high specificity and a positive diagnostic LR5 that indicates at least a moderate increase in 
the pre-screen to post-screen risk probability (Jaeschke et al. 1994). The screen’s discriminant 
accuracy should also not be largely mediated by confounding conditions, such as comorbid depressive 
or anxiety disorders (Janes and Pepe 2008), but its items/components should possess strong content 
and convergent validity (i.e., indeed measure the target condition) (Dawe et al. 2002). When tested 
alongside the gold standard of a clinical interview, questionnaire items should highly correlate with 
their interview counterpart and final screen results should correlate highly with interview results (i.e., 
have excellent convergent validity) (Dawe et al. 2002). In addition, the screener should assess all 
aspects of the condition (i.e., possess good content validity). Since the assessment of BS criteria is 
time-consuming and requires intensive training, and BS assessments completely rely on the patient’s 
self-experience even during a clinical interview, we explored whether the FCQ might be used as a 
screener for psychosis-risk according to BS criteria. 
Surprisingly, the convergent validity of the assessment of BS by the FCQ was generally insufficient 
despite the subjective nature of BS and their general reliance on self-reporting (Schultze-Lutter 2009). 
Additionally, its concurrent validity with regard to BS criteria was not satisfactory. Although BS rely 
less on interviewer appraisal than attenuated positive symptoms, the FCQ’s concurrent validity is only 
as good as that reported among self-report assessments of attenuated positive symptoms when a cut-
off is chosen that optimises both sensitivity and specificity (Kline and Schiffman 2014). Thus, in line 
with reports on differences between self-report and clinical assessments of BS and attenuated positive 
symptoms (Granö et al. 2011; Maß et al. 1997; Ochoa et al. 2008; Schultze-Lutter et al. 2014; Yung et 
al. 2009), we found a significant overestimation of clinician-rated BS by self-rated BS. 
Only the criteria-relevant BS ‘changes in colour vision’ and ‘micropsia, macropsia’ were 
unequivocally valid in terms of possessing both sufficient CR and κ. Interestingly, it was also a visual 
perception disturbance, ‘blurred vision’, that previously demonstrated the highest correlation between 
the interview (BSABS) and self-rating (FCQ) assessment (r=0.51) (Maß et al. 1997). This symptom 
however is one of the few criteria-irrelevant perception disturbances (Klosterkötter et al. 2001) and not 
included in SPI-A/SPI-CY; consequently, it was not analysed in our study. Furthermore, perceptual 
disturbances have previously shown the highest agreement between self-report and interview versions 
of the PROD-Screen (Granö et al. 2011). Contrary to our results however, acoustic perception 
disturbances in the PROD-Screen returned a much higher  (0.964) than visual ones (0.453). 
However, PROD-Screen’s acoustic perception disturbances also include hallucinations while its visual 
perception disturbances remain equivalent to perceptual distortions and are therefore comparable to 
BS (Granö et al. 2011). Consequently, our finding of =0.320 for visual perception disturbances is 
more comparable to PROD-screen results than the finding of =0.249 for acoustic perception 
disturbances. 
For all other BS included in both FCQ and SPI-A/SPI-CY, agreement between assessment modes was 
at most slight and therefore insufficient. The influence of item wording on convergent validity was 
sometimes impressive, for example,  varied between 0.090 and 0.259 for the eight alternative FCQ-
items assessing ‘disturbances of receptive speech’, and even between 0.053 and 0.301 for the three 
FCQ-items assessing ‘disturbances of expressive speech’. The influence of wording on convergent 
validity has not yet been considered in the construction or translation of early detection screeners that 
were predominately guided by aspects of face validity. Convergent validity however might also affect 
the concurrent and predictive validity. The impact of different symptom formulations on convergent 
validity should therefore be examined for future screeners, their revisions and translations. 
With regards to the two BS criteria, COPER and COGDIS,  and CRs clearly indicated an insufficient 
clinical usefulness of the FCQ for their assessment; the FCQ overestimated the presence of COPER by 
29.6% and that of COGDIS by 58%. Thereby, COGDIS exhibited a much larger discrepancy between 
the results of self-reports and interviews for a psychosis-risk status than the 29.9% discrepancy 
reported for the PROD-screen (Granö et al. 2011) which was comparable with the results for COPER. 
Even when examining a more criteria-independent assessment of the FCQ’s concurrent validity, our 
findings were no more positive. Both negative and positive LRs were clearly insufficient according to 
their guidelines (Jaeschke et al. 1994) for both FCQ-total and the total of criteria-relevant BS-FCQ. 
Notably, our sensitivity and specificity values were reasonably comparable to those reported for 
screeners for ultra-high risk status (Kline and Schiffman 2014). This indicates that LRs as measures of 
concurrent validity should generally be taken into account to ensure proper validation of screeners. 
An advantage of our study is that we not only evaluated the concurrent validity of the FCQ for 
distinguishing between risk and no-risk, but also examined the FCQ’s convergent validity, i.e., the 
extent to that it actually measures what it is supposed to measure. To date, emphasis in the 
examination of mainly ultra-high risk screeners has been placed on concurrent validity irrespective of 
convergent validity. The neglect of convergent validity has arguably resulted in distorted reports 
however. For example, all three scales of the Community Assessment of Psychotic Experiences 
(Stefanis et al. 2002) were considered accurate in discriminating  ultra-high risk status (Hanssen et al. 
2003; Konings et al. 2006; Mossenheb et al. 2012; Stefanis et al. 2002), but taken in context, only the 
positive symptoms scale (not the negative and depressive subscales) relates to ultra-high risk criteria. 
The sample size in this study was comparable to other screening evaluation studies in clinical samples 
(Kline and Schiffman 2014; Schultze-Lutter et al. 2014) and was also sufficient to detect a clinical 
useful  against the null hypothesis of no agreement between assessment modes with a power of 90% 
(Sim et al. 2005). A clear disadvantage of the current study was however shown in the limited content 
validity of the FCQ as a result of the incomplete overlap between the BS included in FCQ and SPI-
A/SPI-CY. This precluded an examination of the criteria-relevant BS of ‘disturbances of abstract 
thinking’, ‘unstable ideas of reference’, ‘thought perseveration’, ‘derealisation’, as well as of two 
acoustic and five visual perception disturbances. 
In conclusion, despite their subjective nature and reliance on self-report, the assessment of BS by the 
FCQ appears to be no more valid than the self-report screeners of attenuated psychotic symptoms or  
ultra-high risk criteria and, particularly for lack of content validity, cannot be recommended as a 
psychosis-risk screener of BS criteria. With respect to the apparent influence of item wording on 
convergent validity, a future screener should first ensure items’ convergent validity before 
investigating concurrent validity, i.e., the power to discriminate patients with and without BS criteria. 
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Table 1: Basic symptom criteria 
Risk criterion ‘Cognitive-Perceptive Basic Symptoms’ (COPER) 
 At least any 1 of the following basic symptoms with a SPI-A score of ≥3 within the last 3 
months: 
 thought interference 
 thought perseveration 
 thought pressure 
 thought blockages 
 disturbance of receptive speech 
 decreased ability to discriminate between ideas and perception, fantasy and true 
memories 
 unstable ideas of reference 
 derealisation 
 visual perception disturbances (excl. hypersensitivity to light or blurred vision) 
 acoustic perception disturbances (excl. hypersensitivity to sounds) 
 First occurrence ≥12 months ago 
High-risk criterion ‘Cognitive Disturbances’ (COGDIS) 
 At least any 2 of the following basic symptoms with a SPI-A score of ≥3 within the last 3 
months: 
 inability to divide attention 
 thought interference 
 thought pressure 
 thought blockages 
 disturbance of receptive speech 
 disturbance of expressive speech 
 unstable ideas of reference  
 disturbances of abstract thinking 
 captivation of attention by details of the visual field 
 
Table 2: Sociodemographic and clinical characteristics 
 
Patients 
(N=81) 
Age in years: M±SD (range) 20±6(9-40) 
Minors (<18 yrs.): n (%) 
Male gender: n (%)  
40 (49%) 
46 (57%) 
Current psychosocial functioning (SOFAS): Mdn (range) 65 (35-85) 
Main clinical diagnosis according to ICD-10: n (%)  
Mental and behavioral disorders due to psychoactive substance use (F1)  2 (2%) 
Schizophrenia, schizotypal and delusional disorders (F2)  8 (10%) 
Mood (affective) disorders (F3)  17 (21%) 
Neurotic, stress-related and somatoform disorders (F4)  4 (5%) 
Disorders of adult personality and behavior (F6)  1 (1%) 
Disorders of psychological development (F8)  1 (1%) 
Behavioral and emotional disorders with onset usually occurring in 
childhood and adolescence (F9) and unspecified mental disorder (F9) 15 (19%) 
Any 1 at-risk criteriona: n (%) 33 (41%) 
COPER 17 (21%) 
COGDIS 12 (15%) 
APS 21 (26%) 
BLIPS 2 (2%) 
a Multiple criteria possible; COPER: cognitive-perceptive basic symptoms; COGDIS: cognitive disturbances; APS: 
attenuated psychotic symptoms; BLIPS: brief limited intermittent psychotic symptoms 
Table 3: Criteria-relevant BS: Agreement on symptom presence of self-reported BS assessed with the ‘Frankfurt Complaint Questionnaire’ (FCQ) 
and clinician-rated BS assessed with the ‘Schizophrenia Proneness Instrument’ (SPI-A / SPI-CY), and on presence of risk criteria “cognitive-
perceptive basic symptoms” (COPER) and “cognitive disturbances” (COGDIS) 
 
FCQ items SPI-A / SPI-CY items Correspondence rate Kappa (κ)
a Prevalence index (PI)b 
% present in 
FCQ 
% present in 
SPI-A / SPI-
CY
FCQ 80 (n=81) Inability to divide attention (B1 / D8)c 72.84% 0.314 0.531 37.04% 9.88% 
FCQ 31, 66, 71(n=81; any 
1) 
Disturbance of expressive speech (C5 / D12)d 69.14% 0.215 0.519 35.80% 12.35% 
 FCQ 31 (n=81)  76.54% 0.053 0.716 14.81% 12.35% 
 FCQ 66 (n=81)  74.07% 0.301 0.568 28.40% 12.35% 
 FCQ 71e (n=81)  76.54% 0.251 0.642 20.99% 12.35% 
FCQ 32 (n=81) Captivation of attention by details of the visual 
field (O7 / O2)d
79.01% 0.120 0.741 20.99% 4.94% 
FCQ 13, 54 (any 1; n=81) Thought interference (C2 / D9)c,d 48.15% 0.137 0.259 62.96% 11.11% 
 FCQ 13 (n=81)  56.79% 0.190 0.346 54.32% 11.11% 
 FCQ 54 (n=79)  69.62% 0.152 0.570 31.65% 11.39% 
FCQ 43, 70 (any 1; n=81) Thought blockages (C3 / D15) c,d 58.02% 0.215 0.062 60.49% 33.33% 
 FCQ 43 (n=79)  59.49% 0.179 0.185 48.10% 32.91% 
 FCQ 70 (n=79)  63.29% 0.236 0.228 44.30% 32.91% 
FCQ 37, 40, 69, 82, 90, 
93, 94 (any 1; n=81)
Disturbance of receptive speech (C4 / D11) c,d 34.57% 0.051 0.222 71.60% 6.17% 
 FCQ 37 (n=80)  57.50% 0.090 0.475 46.25% 6.25% 
 FCQ 40 (n=80)  78.75% 0.244 0.688 25.00% 6.25% 
 FCQ 69 (n=79)  65.82% 0.181 0.532 40.51% 6.33% 
 FCQ 82 (n=79)  62.03% 0.113 0.519 41.77% 6.33% 
 FCQ 90 (n=79)  68.35% 0.098 0.608 32.91% 6.33% 
 FCQ 93 (n=79)  72.15% 0.180 0.620 31.65% 6.33% 
 FCQ 94 (n=79)  79.75% 0.259 0.696 24.05% 6.33% 
FCQ 2, 36, 85 (any 1; 
n=81) 
Thought pressure (D3 / D10) c,d 43.21% 0.099 0.185 67.90% 13.58% 
 FCQ 2 (n=81)  59.26% 0.207 0.346 51.85% 13.58% 
 FCQ 36 (n=79)  54.43% 0.113 0.342 51.90% 13.92% 
 FCQ 85e (n=79)  62.96% 0.161 0.543 38.27% 13.92% 
FCQ 76 (n=81) Decreased ability to discriminate between ideas 
and perception, fantasy and true memories (O2 / 
B1)c 
75.31% 0.179 0.654 25.93% 8.64% 
FCQ 63, 47, 14, 19, 84, 
24, 29, 45, 50, 51, 79 (any 
1; n=81) 
Visual perception disturbances (O4 / B3)c 65.82% 0.320 0.177 50.63% 31.65% 
 FCQ 63 (n=78) Partial seeing including tubular vision (O4.10 / 
O.1) 
88.46% 0.248 0.833 10.26% 6.41% 
 FCQ 47 (n=79) Photopsia (F2 / O3) 81.01% 0.256 0.709 20.25% 8.86% 
 FCQ 14 (n=81 Changed perception of the face or body of 
others (D5 / B3.5)
88.89% 0.353 0.815 13.58% 4.94% 
 FCQ 19 (n=81) Metamorphopsia (O4.2 / B3.3) 85.19% 0.105 0.827 14.81% 2.47%  FCQ 84 (n=79) 90.12% -0.035 0.901 5.06% 2.53% 
 FCQ 24e (n=81) Changes in colour vision (O4.3 / B3.4) 90.12% 0.501 0.778 12.35% 9.88% 
 FCQ 29 (n=79) Micropsia, macropsia (F3 / B3.2) 93.67% 0.581 0.835 7.59% 8.86% 
 FCQ 45 (n=79) Disturbances of the estimation of distances or 
sizes (O4.7 / B3.9)
84.81% 0.171 0.797 12.66% 7.59% 
 FCQ 50e (n=78)
Pseudomovements of optic stimuli (O4.5 / B3.7)
84.62% 0.066 0.790 11.54% 6.41% 
 FCQ 51 (n=78) 91.03% 0.175 0.885 5.13% 6.41% 
 FCQ 79 (n=76) 90.79% 0.079 0.776 10.53% 6.58% 
FCQ 25, 53, 72 (any 1; 
n=80) 
Acoustic perception disturbances (O5 / B5)c 72.50% 0.249 0.575 33.75% 8.75% 
 FCQ 25 (n=80) Changed intensity/quality of acoustic stimuli 
(F5 / B5.1) 
83.75% 0.299 0.738 17.5% 8.75% 
 FCQ 53 (n=78) 76.92% 0.257 0.617 26.92% 8.97% 
 FCQ 72 (n=78) 87.18% 0.305 0.795 11.54% 8.97% 
COPER (≥1 BS of 7)f,g COPER (≥1 BS of 7)f,g 67.90% 0.228 0.506 90.12% 60.49% 
COGDIS (≥2 BS of 7)f,g COGDIS (≥2 BS of 7)f,g 41.98% 0.130 0.049 81.48% 23.46% 
a   Evaluation guidelines for κ: 0.00–0.20 = slight, 0.21–0.40 = fair, 0.41–0.60 = moderate, 0.61–0.80 = substantial, and 0.81–1.00 = almost perfect agreement 
b   A high prevalence index represents a low prevalence rate, whereas a low prevalence index represents a high prevalence rate. 
c   Symptom is part of COPER 
d   Symptom is part of COGDIS 
e   Item was not part of the initially described correspondence between FCQ and BSABS by Süllwold & Huber (1986); the assignment was made by F.S.L. 
f If BS is assessed in the FCQ by several items, at least any 1 of them was rated as presence of BS. 
g   The following BS (SPI-A number / SPI-CY number) that are part of COPER or COGDIS are not assessed in the FCQ: disturbances of abstract thinking (O3 / D7), unstable ideas of reference (D4 
/ B2), thought perseveration (O1 / D14), derealization (O8 / B7), and some of the acoustic and visual perception disturbances. 
Table 4: Unspecific BS: Agreement on symptom presence of self-reported BS assessed with the ‘Frankfurt Complaint Questionnaire’ (FCQ) and 
clinician-rated BS assessed with the ‘Schizophrenia Proneness Instrument (SPI-A / SPI-CY) 
 
FCQ items SPI-A / SPI-CY items Correspondence 
rate Kappa (κ)a 
Prevalence 
index (PI)b 
% present in 
FCQ 
% present in 
SPI-A / SPI-
CY 
FCQ 16 (n=81) Change in mood, emotional responsiveness (A2 / 
A5) 
72.84% 0.441 0.210 66.67% 55.56% 
FCQ 87 (n=76) Decreased capacity to discriminate between different 
kinds of emotions (D1 / D13) 
70.37% 0.164 0.605 23.68% 11.84% 
FCQ 59, 96 (any 1;n=33) Disturbance in presenting oneself (- / A8) 63.64% 0.092 0.613 39.39% 3.03% 
FCQ 56, 57 (any 1; n=79) Impaired tolerance to unusual, unexpected or 
specific novel demands (A1.1 / A4.2) 
40.51% 0.024 0.000 73.41% 26.58% 
FCQ 61, 89, 97 (any 1; 
n=79) 
Impaired tolerance to certain social everyday 
situations (A1.2 / A4.3) 
59.49% 0.187 0.139 49.37% 36.71% 
FCQ 39, 98 (any 1; n=79) Difficulties concentrating (B3 / A11) 67.09% 0.283 0.291 67.09% 62.03% 
FCQ 8, 78, 83c (any 1; 
n=40) 
Disturbance in retrieving knowledge from long-term 
memory (- / D6) 
45.00% 0.000 0.450 55.00% 0.0% 
FCQ 48c, 73c (any 1; 
n=79) 
Difficulties holding things in mind for less than an 
hour (B4 / D5) 
62.03% 0.275 0.063 58.23% 35.44% 
FCQ 27 (n=39) Disturbance of the comprehension of visual or 
acoustic stimuli (- / B6) 
66.67% 0.090 0.615 35.90% 2.56% 
FCQ 10c, 58, 65c (any 1; 
n=80) 
Feeling overly distracted by stimuli (B2 / D16) 62.50% 0.257 0.075 60.00% 47.50% 
FCQ 20c, 22, 33, 81 (any 
1; n=80) 
Motor interference exceeding simple lack of co-
ordination (O9 / D17) 
56.25% -0.025 0.563 42.50% 1.25% 
FCQ 7c, 34, 86 (any 1; 
n=80) 
Motor blockages (O10 / D18) 52.50% 0.050 0.475 50.00% 2.50% 
FCQ 6, 11, 17, 38, 44, 46, 
77, 95 (any 1; n=80) 
Loss of automatic skills (O11 / D19) 32.50% 0.031 0.263 71.25% 3.75% 
FCQ 9 (n=81) Somatopsychic bodily depersonalization (F6 / B8.2) 85.19% 0.173 0.802 12.35% 7.41% 
FCQ 18 (n=40) Bodily sensations of abnormal heaviness, lightness, 
emptiness, falling, sinking, levitation or elevation (- 
/B8.6) 
87.50% -0.042 0.875 10.00% 2.50% 
a   Evaluation guidelines for κ: 0.00–0.20 = slight, 0.21–0.40 = fair, 0.41–0.60 = moderate, 0.61–0.80 = substantial, and 0.81–1.00 = almost perfect agreement 
b A high prevalence index represents a low prevalence rate, whereas a low prevalence index represents a high prevalence  rate 
c  Item was not part of the initially described correspondence between FCQ and BSABS by Süllwold & Huber (1986); the assignment was made by F.S.L. 
Table 5: Diagnostic accuracy of the cut-off of the FCQ total score and of the sum score of FCQ criteria-relevant BSs 
 
FCQ threshold Sensitivity Specificity Positive Predictive Value
Negative Predictive 
Value
Positive likelihood 
ratio(LR+)a
Negative likelihood 
ratio(LR-)a
FCQ total score ≥24 0.673 0.656 0.750 0.568 1.956 0.498
FCQ criteria-relevant BS ≥8 0.578 0.710 0.743 0.537 1.993 0.594
a According to the guidelines (Jaeschke et al. 1994) a LR+ of <3 and a LR- of >0.3 generate small and rarely important changes in pre-test probabilities. 
 
 
Fig. 1: Overall ability of the FCQ total score and of the total score of FCQ-assessed basic symptoms 
included in COPER/COGDIS for discriminating patients who had met COPER/COGDIS in the 
clinical interview from those who did not: Areas under the ROC curve. 
Supplementary Table 1: Sociodemographic and clinical characteristics of the subsample 
of ≥16-year-olds 
 
Patients 
(N=62) 
Age in years: M±SD (range) 22±5(16-40) 
Male gender: n (%)  37 (60%) 
Current psychosocial functioning (SOFAS): Mdn (range) 61(35-85) 
Main clinical diagnosis according to ICD-10: n (%)  
Mental and behavioral disorders due to psychoactive substance use (F1)  2 (3%) 
Schizophrenia, schizotypal and delusional disorders (F2)  7 (11%) 
Mood (affective) disorders (F3)  14 (23%) 
Neurotic, stress-related and somatoform disorders (F4)  3 (5%) 
Disorders of adult personality and behavior (F6)  1 (2%) 
Disorders of psychological development (F8)  1 (2%) 
Behavioral and emotional disorders with onset usually occurring in 
childhood and adolescence (F9) and unspecified mental disorder (F9) 4 (6%) 
Any 1 at-risk criteriona: n (%) 26 (42%) 
COPER 16 (26%) 
COGDIS 11 (18%) 
APS 15 (24%) 
BLIPS 2 (3%) 
a Multiple criteria possible; COPER: cognitive-perceptive basic symptoms; COGDIS: cognitive disturbances; APS: 
attenuated psychotic symptoms; BLIPS: brief limited intermittent psychotic symptoms 
Supplementary Table 2: Criteria-relevant BS: Agreement on symptom presence of self-reported BS assessed with the ‘Frankfurt Complaint 
Questionnaire’ (FCQ) and clinician-rated BS assessed with the ‘Schizophrenia Proneness Instrument’ (SPI-A / SPI-CY), and on presence of risk 
criteria “cognitive-perceptive basic symptoms” (COPER) and “cognitive disturbances” (COGDIS) for the total sample (n=81) and a subsample 
of ≥16-year-olds (n=62). 
 
FCQ items 
Total sample (n=81) 
Only 16-40 years (n=62)
SPI-A / SPI-CY items Correspondence rate Kappa (κ)
a Prevalence index (PI)b 
% present in 
FCQ 
% present in 
SPI-A / SPI-
CY
FCQ 80 (n=81) Inability to divide attention (B1 / D8)c
 
72.84%
75.81% 
0.314
0.402 
0.531
0.500 
37.04%
37.10% 
9.88% 
12.90% 
FCQ 31, 66, 71(n=81; any 
1) 
Disturbance of expressive speech (C5 / D12)d
 
69.14%
69.35% 
0.215
0.257 
0.519
0.467 
35.80%
37.10% 
12.35% 
16.13% 
 FCQ 31 (n=81)  76.54%
74.19%
0.053
0.046
0.716
0.677
14.81%
16.12%
12.35% 
16.12% 
 FCQ 66 (n=81)  74.07%
77.42%
0.301
0.369
0.568
0.548
28.40%
29.03%
12.35% 
16.12% 
 FCQ 71e (n=81)  76.54%
77.42%
0.251
0.281
0.642
0.613
20.99%
22.58%
12.35% 
16.12% 
FCQ 32 (n=81) Captivation of attention by details of the visual 
field (O7 / O2)d
79.01%
75.81%
0.120
0.041
0.741
0.726
20.99%
22.58%
4.94% 
4.84% 
FCQ 13, 54 (any 1; n=81) Thought interference (C2 / D9)c,d 48.15%
48.39%
0.137
0.151
0.259
0.226
62.96%
64.52%
11.11% 
12.90% 
 FCQ 13 (n=81)  56.79%
53.23%
0.190
0.182
0.346
0.274
54.32%
59.68%
11.11% 
12.90% 
 FCQ 54 (n=79)  69.62%
72.58%
0.152
0.231
0.570
0.565
31.65%
30.65%
11.39% 
12.90% 
FCQ 43, 70 (any 1; n=81) Thought blockages (C3 / D15) c,d 58.02%
58.06%
0.215
0.214
0.062
0.000
60.49%
62.90%
33.33% 
37.10% 
 FCQ 43 (n=79)  59.49%
58.06%
0.179
0.161
0.185
0.129
48.10%
50.00%
32.91% 
37.10% 
 FCQ 70 (n=79)  63.29%
59.68%
0.236
0.173
0.228
0.177
44.30%
45.16%
32.91% 
37.10% 
FCQ 37, 40, 69, 82, 90, 
93, 94 (any 1; n=81)
Disturbance of receptive speech (C4 / D11) c,d 34.57%
33.87%
0.051
0.059
0.222
0.177
71.60%
74.19%
6.17% 
8.06% 
 FCQ 37 (n=80)  57.50%
54.84%
0.090
0.097
0.475
0.419
46.25%
50.00%
6.25% 
8.06% 
 FCQ 40 (n=80)  78.75%
79.03%
0.244
0.294
0.688
0.661
25.00%
25.81%
6.25% 
8.06% 
 FCQ 69 (n=79)  65.82%
61.29%
0.181
0.182
0.532
0.452
40.51%
46.77%
6.33% 
8.06% 
 FCQ 82 (n=79)  62.03%
61.29%
0.113
0.132
0.519
0.484
41.77%
43.55%
6.33% 
8.06% 
 FCQ 90 (n=79)  68.35%
62.90%
0.098
0.085
0.608
0.532
32.91%
38.71%
6.33% 
8.06% 
 FCQ 93 (n=79)  72.15%
69.35%
0.180
0.190
0.620
0.565
31.65%
35.48%
6.33% 
8.06% 
 FCQ 94 (n=79)  79.75%
79.03%
0.259
0.294
0.696
0.661
24.05%
25.81%
6.33% 
8.06% 
FCQ 2, 36, 85 (any 1; 
n=81) 
Thought pressure (D3 / D10) c,d 43.21%
43.55%
0.099
0.111
0.185
0.113
67.90%
70.97%
13.58% 
17.75% 
 FCQ 2 (n=81)  59.26%
59.68%
0.207
0.241
0.346
0.274
51.85%
54.84%
13.58% 
17.74% 
 FCQ 36 (n=79)  54.43%
51.61% 
0.113
0.107 
0.342
0.258 
51.90%
56.45% 
13.92% 
17.74% 
 FCQ 85e (n=79)  62.96%
64.52%
0.161
0.189
0.543
0.419
38.27%
40.32%
13.92% 
17.74% 
FCQ 76 (n=81) Decreased ability to discriminate between ideas 
and perception, fantasy and true memories (O2 / 
B1)c 
75.31%
70.97% 
0.179
0.171 
0.654
0.581 
25.93%
30.65% 
8.64% 
11.29% 
FCQ 63, 47, 14, 19, 84, 
24, 29, 45, 50, 51, 79 (any 
1; n=81) 
Visual perception disturbances (O4 / B3)c 65.82%
69.35% 
0.320
0.401 
0.177
0.145 
50.63%
53.23% 
31.65% 
31.75% 
 FCQ 63 (n=78) Partial seeing including tubular vision (O4.10 / 
O.1) 
88.46%
90.16%
0.248
0.349
0.833
0.836
10.26%
9.84%
6.41% 
6.56% 
 FCQ 47 (n=79) Photopsia (F2 / O3) 81.01%
83.87%
0.256
0.371
0.709
0.710
20.25%
20.97%
8.86% 
8.06% 
 FCQ 14 (n=81 Changed perception of the face or body of 
others (D5 / B3.5)
88.89%
88.71%
0.353
0.315
0.815
0.822
13.58%
12.90%
4.94% 
4.84% 
 FCQ 19 (n=81)
Metamorphopsia (O4.2 / B3.3) 
85.19%
85.48%
0.105
0.136
0.827
0.823
14.81%
14.52%
2.47% 
3.23% 
 FCQ 84 (n=79) 90.12%
91.94%
-0.035
-0.040
0.901
0.919
5.06%
4.84%
2.53% 
3.23% 
 FCQ 24e (n=81) Changes in colour vision (O4.3 / B3.4) 90.12%
88.71%
0.501
0.523
0.778
0.726
12.35%
14.52%
9.88% 
12.90% 
 FCQ 29 (n=79) Micropsia, macropsia (F3 / B3.2) 93.67%
95.16%
0.581
0.703
0.835
0.823
7.59%
6.45%
8.86% 
11.29% 
 FCQ 45 (n=79) Disturbances of the estimation of distances or 
sizes (O4.7 / B3.9)
84.81%
83.87%
0.171
0.197
0.797
0.774
12.66%
12.90%
7.59% 
9.68% 
 FCQ 50e (n=78)
Pseudomovements of optic stimuli (O4.5 / B3.7)
84.62%
80.33%
0.066
0.042
0.790
0.770
11.54%
14.75%
6.41% 
8.20% 
 FCQ 51 (n=78) 91.03%
88.52%
0.175
0.161
0.885
0.839
5.13%
6.56%
6.41% 
8.20% 
 FCQ 79 (n=76) 90.79%
83.05%
0.079
0.075
0.776
0.758
10.53%
11.86%
6.58% 
8.20% 
FCQ 25, 53, 72 (any 1; 
n=80) 
Acoustic perception disturbances (O5 / B5)c 72.50%
72.58%
0.249
0.237
0.575
0.597
33.75%
33.87%
8.75% 
6.45% 
 FCQ 25 (n=80)
Changed intensity/quality of acoustic stimuli 
(F5 / B5.1) 
83.75%
87.10%
0.299
0.446
0.738
0.742
17.5%
19.35%
8.75% 
6.45% 
 FCQ 53 (n=78) 76.92%
77.42%
0.257
0.219
0.617
0.677
26.92%
25.81%
8.97% 
6.45% 
 FCQ 72 (n=78) 87.18%
87.10%
0.305
0.371
0.795
0.774
11.54%
16.13%
8.97% 
6.45% 
COPER (≥1 BS of 7)f,g COPER (≥1 BS of 7)f,g 67.90%70.96%
0.228
0.242
0.506
0.548
90.12%
90.32%
60.49% 
64.52% 
COGDIS (≥2 BS of 7)f,g COGDIS (≥2 BS of 7)f,g 41.98%45.16%
0.130
0.146
0.049
0.129
81.48%
83.87%
23.46% 
29.03% 
a   Evaluation guidelines for κ: 0.00–0.20 = slight, 0.21–0.40 = fair, 0.41–0.60 = moderate, 0.61–0.80 = substantial, and 0.81–1.00 = almost perfect agreement 
b   A high prevalence index represents a low prevalence rate, whereas a low prevalence index represents a high prevalence rate. 
c   Symptom is part of COPER 
d   Symptom is part of COGDIS 
e   Item was not part of the initially described correspondence between FCQ and BSABS by Süllwold & Huber (1986); the assignment was made by F.S.L. 
f If BS is assessed in the FCQ by several items, at least any 1 of them was rated as presence of BS. 
g   The following BS (SPI-A number / SPI-CY number) that are part of COPER or COGDIS are not assessed in the FCQ: disturbances of abstract thinking (O3 / D7), unstable ideas of reference 
(D4 / B2), thought perseveration (O1 / D14), derealization (O8 / B7), and some of the acoustic and visual perception disturbances. 
Supplementary Table 3: Unspecific BS: Agreement on symptom presence of self-reported BS assessed with the ‘Frankfurt Complaint Questionnaire’ 
(FCQ) and clinician-rated BS assessed with the ‘Schizophrenia Proneness Instrument (SPI-A / SPI-CY) for the total sample (n=81) and a subsample 
of ≥16-year-olds (n=62). 
 
FCQ items 
Total sample 
Only 16-40 years 
SPI-A / SPI-CY items 
 Correspondence rate Kappa (κ)
a Prevalence index (PI)b 
% present in 
FCQ 
% present in 
SPI-A / SPI-
CY 
FCQ 16 (n=81) Change in mood, emotional responsiveness (A2 / 
A5) 
72.84% 
72.58% 
0.441 
0.415 
0.210 
0.274 
66.67% 
58.06% 
55.56% 
69.35% 
FCQ 87 (n=76) Decreased capacity to discriminate between different 
kinds of emotions (D1 / D13) 
70.37% 
76.27% 
0.164 
0.100 
0.605 
0.695 
23.68% 
20.34% 
11.84% 
10.17% 
FCQ 59, 96 (any 1;n=33) Disturbance in presenting oneself (- / A8) 63.64% 
55.56% 
0.092 
0.000 
0.613 
0.556 
39.39% 
44.44% 
3.03% 
0.0% 
FCQ 56, 57 (any 1; n=79) Impaired tolerance to unusual, unexpected or 
specific novel demands (A1.1 / A4.2) 
40.51% 
40.32% 
0.024 
-0.003 
0.000 
0.016 
73.41% 
72.58% 
26.58% 
29.03% 
FCQ 61, 89, 97 (any 1; 
n=79) 
Impaired tolerance to certain social everyday 
situations (A1.2 / A4.3) 
59.49% 
58.06% 
0.187 
0.168 
0.139 
0.032 
49.37% 
53.23% 
36.71% 
43.55% 
FCQ 39, 98 (any 1; n=79) Difficulties concentrating (B3 / A11) 67.09% 
66.13% 
0.283 
0.237 
0.291 
0.339 
67.09% 
69.35% 
62.03% 
64.52% 
FCQ 8, 78, 83c (any 1; 
n=40) 
Disturbance in retrieving knowledge from long-term 
memory (- / D6) 
45.00% 
38.10% 
0.000 
0.000 
0.450 
0.381 
55.00% 
20.97% 
0.0% 
0.0% 
FCQ 48c, 73c (any 1; 
n=79) 
Difficulties holding things in mind for less than an 
hour (B4 / D5) 
62.03% 
62.90% 
0.275 
0.289 
0.063 
0.016 
58.23% 
59.68% 
35.44% 
38.71% 
FCQ 27 (n=39) Disturbance of the comprehension of visual or 
acoustic stimuli (- / B6) 
66.67% 
61.90% 
0.090 
0.125 
0.615 
0.524 
35.90% 
42.86% 
2.56% 
4.76 
FCQ 10c, 58, 65c (any 1; 
n=80) 
Feeling overly distracted by stimuli (B2 / D16) 62.50% 
60.56% 
0.257 
0.234 
0.075 
0.016 
60.00% 
59.02% 
47.50% 
42.62% 
FCQ 20c, 22, 33, 81 (any 
1; n=80) 
Motor interference exceeding simple lack of co-
ordination (O9 / D17) 
56.25% 
52.50% 
-0.025 
-0.033 
0.563 
0.574 
42.50% 
40.98% 
1.25% 
1.64% 
FCQ 7c, 34, 86 (any 1; 
n=80) 
Motor blockages (O10 / D18) 52.50% 
49.18% 
0.050 
0.056 
0.475 
0.426 
50.00% 
54.10% 
2.50% 
3.28% 
FCQ 6, 11, 17, 38, 44, 46, 
77, 95 (any 1; n=80) 
Loss of automatic skills (O11 / D19) 32.50% 
34.43% 
0.031 
0.042 
0.263 
0.246 
71.25% 
70.49% 
3.75% 
4.92% 
FCQ 9 (n=81) Somatopsychic bodily depersonalization (F6 / B8.2) 85.19% 0.173 0.802 12.35% 7.41% 
83.87% 0.203 0.774 14.52% 8.06% 
FCQ 18 (n=40) Bodily sensations of abnormal heaviness, lightness, 
emptiness, falling, sinking, levitation or elevation (- 
/B8.6) 
87.50% 
90.48% 
-0.042 
0.000 
0.875 
0.905 
10.00% 
9.52% 
2.50% 
0.0% 
a   Evaluation guidelines for κ: 0.00–0.20 = slight, 0.21–0.40 = fair, 0.41–0.60 = moderate, 0.61–0.80 = substantial, and 0.81–1.00 = almost perfect agreement 
b A high prevalence index represents a low prevalence rate, whereas a low prevalence index represents a high prevalence  rate 
c  Item was not part of the initially described correspondence between FCQ and BSABS by Süllwold & Huber (1986); the assignment was made by F.S.L. 
Supplementary Table 4: Diagnostic accuracy of the cut-off of the FCQ total score and of the sum score of FCQ criteria-relevant BSs for the total 
sample (n=81) and a subsample of ≥16-year-olds (n=62). 
 
FCQ threshold Sensitivity Specificity Positive Predictive Value
Negative Predictive 
Value
Positive likelihood 
ratio(LR+)a
Negative likelihood 
ratio(LR-)a
Relative 
risk 
FCQ total score ≥24
16-40 years 
0.673 
0.750 
0.656
0.682
0.750
0.811
0.568
0.429
1.956
2.358
0.498
0.367
0.577 
0.493 
FCQ criteria-relevant BS ≥8 
16-40 years 
0.578 
0.632 
0.710
0.727
0.743
0.800
0.537
0.533
1.993
2.315
0.594
0.506
0.624 
0.583 
a According to the guidelines (29) a LR+ of <3 and a LR- of >0.3 generate small and rarely important changes in pre-test probabilities. 
